594 related articles for article (PubMed ID: 31647022)
1. Measurable residual disease at myeloablative allogeneic transplantation in adults with acute lymphoblastic leukemia: a retrospective registry study on 2780 patients from the acute leukemia working party of the EBMT.
Pavlů J; Labopin M; Niittyvuopio R; Socié G; Yakoub-Agha I; Wu D; Remenyi P; Passweg J; Beelen DW; Aljurf M; Kröger N; Labussière-Wallet H; Perić Z; Giebel S; Nagler A; Mohty M
J Hematol Oncol; 2019 Oct; 12(1):108. PubMed ID: 31647022
[TBL] [Abstract][Full Text] [Related]
2. Outcome of haploidentical versus matched sibling donors in hematopoietic stem cell transplantation for adult patients with acute lymphoblastic leukemia: a study from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation.
Nagler A; Labopin M; Houhou M; Aljurf M; Mousavi A; Hamladji RM; Al Zahrani M; Bondarenko S; Arat M; Angelucci E; Koc Y; Gülbas Z; Sica S; Bourhis JH; Canaani J; Brissot E; Giebel S; Mohty M
J Hematol Oncol; 2021 Apr; 14(1):53. PubMed ID: 33794963
[TBL] [Abstract][Full Text] [Related]
3. Allogeneic hematopoietic stem cell transplantation for adult patients with t(4;11)(q21;q23) KMT2A/AFF1 B-cell precursor acute lymphoblastic leukemia in first complete remission: impact of pretransplant measurable residual disease (MRD) status. An analysis from the Acute Leukemia Working Party of the EBMT.
Esteve J; Giebel S; Labopin M; Czerw T; Wu D; Volin L; Socié G; Yakoub-Agha I; Maertens J; Cornelissen JJ; Pigneux A; Shimoni A; Schwerdtfeger R; Labussière-Wallet H; Russell N; Schattenberg A; Chevallier P; Koza V; Foà R; Schmid C; Peric Z; Mohty M; Nagler A
Leukemia; 2021 Aug; 35(8):2232-2242. PubMed ID: 33542481
[TBL] [Abstract][Full Text] [Related]
4. Improved Outcomes of Haploidentical Hematopoietic Cell Transplantation with Total Body Irradiation-Based Myeloablative Conditioning in Acute Lymphoblastic Leukemia.
Dholaria B; Labopin M; Angelucci E; Tischer J; Arat M; Ciceri F; Gülbas Z; Ozdogu H; Sica S; Diez-Martin JL; Koc Y; Pavlu J; Socié G; Giebel S; Savani BN; Nagler A; Mohty M
Transplant Cell Ther; 2021 Feb; 27(2):171.e1-171.e8. PubMed ID: 33830029
[TBL] [Abstract][Full Text] [Related]
5. Fludarabine or cyclophosphamide in combination with total body irradiation as myeloablative conditioning prior to allogeneic hematopoietic cell transplantation for acute lymphoblastic leukemia: an analysis by the Acute Leukemia Working Party of the EBMT.
Giebel S; Labopin M; Socié G; Aljurf M; Salmenniemi U; Labussière-Wallet H; Srour M; Kröger N; Zahrani MA; Lioure B; Reményi P; Arat M; Bourhis JH; Helbig G; Tbakhi A; Forcade E; Huynh A; Brissot E; Spirydonidis A; Savani BN; Peric Z; Nagler A; Mohty M
Bone Marrow Transplant; 2023 May; 58(5):506-513. PubMed ID: 36725978
[TBL] [Abstract][Full Text] [Related]
6. Impact of Total Body Irradiation-Based Myeloablative Conditioning Regimens in Patients with Acute Lymphoblastic Leukemia Undergoing Allogeneic Hematopoietic Stem Cell Transplantation: Systematic Review and Meta-Analysis.
Khimani F; Dutta M; Faramand R; Nishihori T; Perez AP; Dean E; Nieder M; Perez L; Mishra A; Elmariah H; Davila M; Ochoa L; Alsina M; Lazaryan A; Bejanyan N; Hansen D; Jain M; Locke F; Liu H; Pidala J; Shah B; Mhaskar R
Transplant Cell Ther; 2021 Jul; 27(7):620.e1-620.e9. PubMed ID: 33798768
[TBL] [Abstract][Full Text] [Related]
7. Pre-transplant MRD negativity predicts favorable outcomes of CAR-T therapy followed by haploidentical HSCT for relapsed/refractory acute lymphoblastic leukemia: a multi-center retrospective study.
Zhao H; Wei J; Wei G; Luo Y; Shi J; Cui Q; Zhao M; Liang A; Zhang Q; Yang J; Li X; Chen J; Song X; Jing H; Li Y; Hao S; Wu W; Tan Y; Yu J; Zhao Y; Lai X; Yin ETS; Wei Y; Li P; Huang J; Wang T; Blaise D; Xiao L; Chang AH; Nagler A; Mohty M; Huang H; Hu Y
J Hematol Oncol; 2020 May; 13(1):42. PubMed ID: 32366260
[TBL] [Abstract][Full Text] [Related]
8. Measurable Residual Disease Assessment and Allogeneic Transplantation as Consolidation Therapy in Adult Acute Lymphoblastic Leukemia in Colombia.
Combariza JF; Arango M; Díaz L; Agudelo C; Hernandez S; Madera AM; León G; Avila V; Bautista L; Valdés J; Orduz R; Mejía F; Moreno L; Ramirez C
Clin Lymphoma Myeloma Leuk; 2021 Apr; 21(4):e365-e372. PubMed ID: 33277225
[TBL] [Abstract][Full Text] [Related]
9. Impact of detectable measurable residual disease on umbilical cord blood transplantation.
Baron F; Labopin M; Ruggeri A; Sierra J; Robinson S; Labussière-Wallet H; Potter M; Ribera JM; Deconinck E; Rambaldi A; Rohrlich PS; de Revel T; Gluckman E; Nagler A; Mohty M
Am J Hematol; 2020 Sep; 95(9):1057-1065. PubMed ID: 32449964
[TBL] [Abstract][Full Text] [Related]
10. FLAMSA-Based Reduced-Intensity Conditioning versus Myeloablative Conditioning in Younger Patients with Relapsed/Refractory Acute Myeloid Leukemia with Active Disease at the Time of Allogeneic Stem Cell Transplantation: An Analysis from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation.
Rodríguez-Arbolí E; Labopin M; Tischer J; Brecht A; Ganser A; Finke J; Blau IW; Kröger N; Kalhs P; Forcade E; Bunjes D; Spyridonidis A; Savani B; Nagler A; Mohty M
Biol Blood Marrow Transplant; 2020 Nov; 26(11):2165-2173. PubMed ID: 32717436
[TBL] [Abstract][Full Text] [Related]
11. Allogeneic HCT for adults with B-cell precursor acute lymphoblastic leukemia harboring IKZF1 gene mutations. A study by the Acute Leukemia Working Party of the EBMT.
Giebel S; Labopin M; Socié G; Beauvais D; Klein S; Wagner-Drouet EM; Blaise D; Nguyen-Quoc S; Bourhis JH; Thiebaut A; Labussière-Wallet H; Charbonnier A; Berceanu A; Diez-Martin JL; Fegueux N; Esteve J; Nagler A; Mohty M
Bone Marrow Transplant; 2021 May; 56(5):1047-1055. PubMed ID: 33235351
[TBL] [Abstract][Full Text] [Related]
12. Comparison of Myeloablative versus Reduced-Intensity Conditioning Regimens in Allogeneic Stem Cell Transplantation Recipients with Acute Myelogenous Leukemia with Measurable Residual Disease-Negative Disease at the Time of Transplantation: A Retrospective Cohort Study.
Yu J; Du Y; Ahmad S; Patel RD; Varela JC; Chang CC; Mori S
Transplant Cell Ther; 2021 Aug; 27(8):663.e1-663.e6. PubMed ID: 33951497
[TBL] [Abstract][Full Text] [Related]
13. Irradiation free conditioning regimen is associated with high relapse rate in Egyptian patients with acute lymphoblastic leukemia following allogeneic hematopoietic stem cell transplantation.
Abdelaty MM; Gawaly A; Fathy GM; Kabbash I; Taha A
J Egypt Natl Canc Inst; 2020 Jun; 32(1):28. PubMed ID: 32537680
[TBL] [Abstract][Full Text] [Related]
14. Reduced-intensity conditioning is a reasonable alternative for Philadelphia chromosome-positive acute lymphoblastic leukemia among elderly patients who have achieved negative minimal residual disease: a report from the Adult Acute Lymphoblastic Leukemia Working Group of the JSHCT.
Akahoshi Y; Nishiwaki S; Arai Y; Harada K; Najima Y; Kanda Y; Shono K; Ota S; Fukuda T; Uchida N; Shiratori S; Tanaka M; Tanaka J; Atsuta Y; Kako S
Bone Marrow Transplant; 2020 Jul; 55(7):1317-1325. PubMed ID: 32447350
[TBL] [Abstract][Full Text] [Related]
15. Total body irradiation versus busulfan based intermediate intensity conditioning for stem cell transplantation in ALL patients >45 years-a registry-based study by the Acute Leukemia Working Party of the EBMT.
Hirschbühl K; Labopin M; Polge E; Blaise D; Bourhis JH; Socié G; Forcade E; Yakoub-Agha I; Labussière-Wallet H; Bethge W; Chevallier P; Bonnet S; Stelljes M; Spyridonidis A; Peric Z; Brissot E; Savani B; Giebel S; Schmid C; Ciceri F; Nagler A; Mohty M
Bone Marrow Transplant; 2023 Aug; 58(8):874-880. PubMed ID: 37147469
[TBL] [Abstract][Full Text] [Related]
16. Measurable residual disease status and outcome of transplant in acute myeloid leukemia in second complete remission: a study by the acute leukemia working party of the EBMT.
Gilleece MH; Shimoni A; Labopin M; Robinson S; Beelen D; Socié G; Unal A; Ganser A; Vitek A; Sengeloev H; Yakoub-Agha I; Tholouli E; Polge E; Mohty M; Nagler A
Blood Cancer J; 2021 May; 11(5):88. PubMed ID: 33980810
[TBL] [Abstract][Full Text] [Related]
17. Minimal residual disease (MRD) positivity at allogeneic hematopoietic cell transplantation, not the quantity of MRD, is a risk factor for relapse of Philadelphia chromosome-positive acute lymphoblastic leukemia.
Akahoshi Y; Arai Y; Nishiwaki S; Mizuta S; Marumo A; Uchida N; Kanda Y; Sakai H; Takada S; Fukuda T; Fujisawa S; Ashida T; Tanaka J; Atsuta Y; Kako S
Int J Hematol; 2021 Jun; 113(6):832-839. PubMed ID: 33570732
[TBL] [Abstract][Full Text] [Related]
18. [Efficacy of allogeneic hematopoietic stem cell transplantation based on a total body irradiation conditioning treatment regimen for adult acute lymphocytic leukemia].
Xiao QQ; Yu XL; Song XC; Hou YX; Deng L; Li WJ; Zhou F
Zhonghua Xue Ye Xue Za Zhi; 2024 Mar; 45(3):249-256. PubMed ID: 38716596
[No Abstract] [Full Text] [Related]
19. Thiotepa-Based Regimens Are Valid Alternatives to Total Body Irradiation-Based Reduced-Intensity Conditioning Regimens in Patients with Acute Lymphoblastic Leukemia: A Retrospective Study on Behalf of the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation.
Battipaglia G; Labopin M; Mielke S; Ruggeri A; Nur Ozkurt Z; Bourhis JH; Rabitsch W; Yakoub-Agha I; Grillo G; Sanz J; Arcese W; Novis Y; Fegueux N; Spyridonidis A; Giebel S; Nagler A; Ciceri F; Mohty M
Transplant Cell Ther; 2024 Jan; 30(1):95.e1-95.e10. PubMed ID: 37816471
[TBL] [Abstract][Full Text] [Related]
20. Autologous versus allogeneic hematopoietic cell transplantation for older patients with acute lymphoblastic leukemia. An analysis from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation.
Giebel S; Labopin M; Houhou M; Caillot D; Finke J; Blaise D; Fegueux N; Ethell M; Cornelissen JJ; Forcade E; Yakoub-Agha I; Lussana F; Maertens J; Bourhis JH; Jindra P; Gorin NC; Nagler A; Mohty M
Bone Marrow Transplant; 2023 Apr; 58(4):393-400. PubMed ID: 36611097
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
